Vestor Capital’s Novo Nordisk NVO Stock Holding History

Vestor Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,404	Closed	-$78K	–	283
2025 Q3	$78K	Buy	+1,404	New	+$82.2K	0.01%	223
2024 Q3	–	Sell	-324	Closed	-$46K	–	258
2024 Q2	$46K	Sell	324 -1,600	-83%	-$212K	﹤0.01%	236
2024 Q1	$247K	Buy	+1,924	New	+$229K	0.02%	125
2023 Q4	–	Sell	-532	Closed	-$48K	–	255
2023 Q3	$48K	Sell	532 -314	-37%	-$27.7K	0.01%	226
2023 Q2	$68K	Buy	+846	New	+$69.1K	0.01%	210

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vestor Capital's NVO Position: Q4 2025 in Review

Vestor Capital sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 1,404 shares — an estimated $78K sold.

Vestor Capital first reported a position in NVO in Q2 2023 and held it in 5 quarters. The position peaked at $247K in Q1 2024. 1,414 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

Vestor Capital reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
Vestor Capital sold 1,404 Novo Nordisk shares in Q4 2025, an estimated $78K.
Vestor Capital first reported a position in Novo Nordisk in Q2 2023 and held it in 5 quarters.
Vestor Capital's Novo Nordisk position peaked at $247K in Q1 2024.
1,414 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Vestor Capital's 13F filing for Q4 2025, filed 11 Feb 2026.